The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors

AIDS

Volumn 12, Issue 7, 1998, Pages 705-712

  Miller, Veronica ^a,g   Stürmer, Martin ^a   Staszewski, Schlomo ^a   Gröschel, Bettina ^a   Hertogs, Kurt ^b   De Béthune, Marie Pierre ^b,d   Pauwels, Rudi ^b   Richard Harrigan, P ^c,e   Bloor, Stuart ^c,f   Kemp, Sharon D ^c,f   Larder, Brendan A ^c,f  

^a GOETHE UNIVERSITY   (Germany)

^b Virco BVBA   (Belgium)

^c GLAXOSMITHKLINE   (United Kingdom)

^d TIBOTEC BVBA   (Belgium)

^e Brit Columbia Ctr Excell HIV/AIDS   (Canada)

^f Virco UK Ltd   (United Kingdom)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cross resistance; Lamivudine; Nucleoside analogue HIV reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; METHIONINE; VALINE;

ARTICLE; CODON; CROSS RESISTANCE; DRUG RESISTANCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIDRUG RESISTANCE; POINT MUTATION; VIROLOGY;

ANTI-HIV AGENTS; COHORT STUDIES; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; METHIONINE; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VALINE; ZALCITABINE; ZIDOVUDINE;

EID: 7144262385     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199807000-00006     Document Type: Article

References (25)

1. Staszewski S, Hill AM, Bartlett J, et al.: Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials: a meta-analysis of controlled trials. AIDS 1997, 11:477-483.
2. CAESAR Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
3. Kuritzkes DR, Quinn JB, Benoit SL, et al.: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
4. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
5. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
6. Kavlick M, Shirasaka T, Kojima E, et al.: Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)2′,3′-dideoxy-3′-thiacytidine. Antiviral Res 1995, 28:133-146.
7. Larder B, Miller V, Staszewski S, et al.: Patterns of drug resistance in HIV-1 isolates from patients treated with AZT and 3TC [abstract]. Antiviral Ther 1996, 1 (suppl 1):61.
8. Tisdale M, Alnadaf T, Cousens D: Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agent Chemother 1997, 41:1094-1098.
9. Mayer D: Clinical significance of drug resistance in HIV-1 infections. AIDS 1996, 10 (suppl 5):S27-S31.
10. Kellam P, Larder BA: Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
11. Hertogs K, de Béthume M-P, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV-1 isolates of patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
12. Larder BA, Kohli A, Kellam P, et al.: Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365:671-673.
13. Gu Z, Gao Q, Li X, et al.: Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Infect Dis 1992, 66:7128-7135.
14. Shirasaka T, Kavlick MF, Ueno T, et al.: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
15. Schafer RW, Iversen AKN, Winter MA, et al.: Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1 infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995, 172:70-78.
16. Schinazi R, Larder B, Mellors J: Mutations in retroviral genes associated with drug resistance, Int Antiviral News 1997, 5:129-142.
17. Pauwels R, Harrigan R, Hertogs K, for the AVANTI Study Group: Correlation between genotypic and phenotypic resistance data in AVANTI. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, October 1997 [abstract 1112].
18. Mayers DL, Japour AJ, Arduino J-M, et al.: Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. The RV43 Study Group. Antimicrob Agents Chemother 1994, 38:307-314.
19. Miller V, Phillips A, Rottmann C, et al.: Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998 (in press).
20. Kemp SD, Bloor S, the FASP Resistance Study Group: Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, June 1997 [abstract 11].
21. Boucher CAB, van Leeuwen R, Kellam P, et al.: Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993, 37:1525-1530.
22. Wakefield JK, Jablonski SA, Morrow CD: In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol 1992, 66:6806-6812.
23. Kuritzkes DR, Bakhtiari M, Shugarts D, et al.: Resistance to lamivudine (3TC) and zidovudine (ZDV) after prolonged treatment with 3TC/ZDV [abstract]. Antiviral Ther 1996, 1 (suppl 1):57.
24. Lanier ER, Stone C, Griffin P, Thomas D, Lafon S: Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral load response. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, January 1998 [abstract 686].
25. Miller V, Staszewski S, Phillips A: Prognostic value of phenotypic AZT-resistance for HIV progression. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 244].